Sean Salmon serves as Executive Vice President and President for the Diabetes Operating Unit (OU) and President for the Cardiovascular Portfolio.
In this dual role, Sean is responsible for the overall strategic direction of the Diabetes OU and its day-to-day global operations. He is also responsible for optimizing Medtronic enterprise performance by supporting capital allocation, talent management, investments, and collaboration to create value across all eight OUs that are organized under the Cardiovascular Portfolio, in addition to the Diabetes OU.
Sean joined Medtronic in 2004 and has held increasingly senior management roles. Most recently as President of Coronary & Structural Heart within our Cardiovascular Portfolio, he led numerous functions including Clinical, Regulatory, R&D, Quality, Health Economics & Reimbursement, Business Development and Strategy. He led Medtronic’s entry into the highly-competitive drug eluting stent market and subsequently diversified the business via organic innovation and acquisitions. He also led the expansion of Medtronic’s fast-growing transcatheter valve replacement (TAVR) business by commercializing multiple product innovations, extending global penetration and by expanding treatment indications.
Sean has nearly 30 years’ experience in the medical device and pharmaceutical industries, with previous roles at C.R. Bard, Johnson & Johnson, SurgiVision and EuroRSCG Life. He earned an MBA from the Kellogg School of Management at Northwestern University and a BS in Applied Physiology from Boston University.
What is Sean Salmon's net worth?
The estimated net worth of Sean Salmon is at least $3.14 million as of December 13th, 2022. Mr. Salmon owns 36,088 shares of Medtronic stock worth more than $3,143,265 as of February 5th. This net worth approximation does not reflect any other investments that Mr. Salmon may own. Learn More about Sean Salmon's net worth.
How do I contact Sean Salmon?
Has Sean Salmon been buying or selling shares of Medtronic?
Sean Salmon has not been actively trading shares of Medtronic during the past quarter. Most recently, Sean Salmon sold 16,631 shares of the business's stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $80.50, for a transaction totalling $1,338,795.50. Following the completion of the sale, the executive vice president now directly owns 36,088 shares of the company's stock, valued at $2,905,084. Learn More on Sean Salmon's trading history.
Who are Medtronic's active insiders?
Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.
Are insiders buying or selling shares of Medtronic?
During the last year, Medtronic insiders bought shares 1 times. They purchased a total of 6,835 shares worth more than $63,428.80. During the last year, insiders at the medical technology company sold shares 4 times. They sold a total of 25,717 shares worth more than $2,241,637.66. The most recent insider tranaction occured on January, 30th when Major Shareholder Plc Medtronic bought 6,835 shares worth more than $63,428.80. Insiders at Medtronic own 0.3% of the company.
Learn More about insider trades at Medtronic. Information on this page was last updated on 1/30/2023.
